SMARAGD: The prospective national clinical research platform to study characteristics, treatment and outcomes of patients with ovarian, fallopian tube, primary peritoneal and endometrial cancer in Germany. 11. November 2022 Decker T, Wöckel A, Juhasz-Böss I, Zaiss M, Nusch A, Gratzke K, u. a. 2022. Oncol Res Treat. 2022;45(suppl 2)(V273):72. Routine care of early breast cancer (stage I-III) in Germany – data of the prospective, intersectoral research platform OPAL. Welt A, Zahn MO, Wöckel A, Stickeler E, Thoma M, Nusch A, u. a. Oncol.Res.Treat. 2022;45 (suppl 2)(P685):211. Download… Weiterlesen Second-line threapies of patients with early progression under CDK4/6-inhibitor in first-line. Data from the registry platform OPAL. Marschner N, Harbeck N, Thill M, Stickeler E, Zaiss M, Nusch A, u. a. 2022. Annals of Oncology. 2022;33(232P):S643. Download… Weiterlesen